Alpha 2.0
Login Register
» Authors » Steven Nijs

Steven Nijs

Explore the profile of Steven Nijs including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 537
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Microbiology
Top 10 Co-Authors
Johan Vingerhoets
Frank Tomaka
Lotke Tambuyzer
Dan H Barouch
Gaston Picchio
Hanneke Schuitemaker
Maria G Pau
Daniel J Stieh
Thomas N Kakuda
James Witek
Published In
Antivir Ther
J Clin Pharmacol
J Infect Dis
J Acquir Immune Defic Syndr
AIDS Res Hum Retroviruses
Affiliations
Soon will be listed here.
Recent Articles
1.
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, et al.
EBioMedicine . 2024 Sep; 108:105320. PMID: 39236556
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based...
2.
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial
Gray G, Mngadi K, Lavreys L, Nijs S, B Gilbert P, Hural J, et al.
Lancet Infect Dis . 2024 Jul; 24(11):1201-1212. PMID: 39038477
Background: HIV type 1 (HIV-1) remains a global health concern, with the greatest burden in sub-Saharan Africa. Despite 40 years of research, no vaccine candidate has shown durable and protective...
3.
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
Stieh D, Barouch D, Comeaux C, Sarnecki M, Stephenson K, Walsh S, et al.
J Infect Dis . 2022 Nov; 227(8):939-950. PMID: 36348617
Background: Developing a cross-clade, globally effective HIV vaccine remains crucial for eliminating HIV. Methods: This placebo-controlled, double-blind, phase 1/2a study enrolled healthy HIV-uninfected adults at low risk for HIV infection....
4.
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
Baden L, Stieh D, Sarnecki M, Walsh S, Tomaras G, Kublin J, et al.
Lancet HIV . 2020 Oct; 7(10):e688-e698. PMID: 33010242
Background: Bioinformatically designed mosaic antigens increase the breadth of HIV vaccine-elicited immunity. This study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 vaccine with the previously...
5.
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)
Stephenson K, Wegmann F, Tomaka F, Walsh S, Tan C, Lavreys L, et al.
Lancet HIV . 2020 Feb; 7(6):e410-e421. PMID: 32078815
Background: Current efficacy studies of a mosaic HIV-1 prophylactic vaccine require four vaccination visits over one year, which is a complex regimen that could prove challenging for vaccine delivery at...
6.
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M, et al.
Lancet . 2018 Jul; 392(10143):232-243. PMID: 30047376
Background: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack...
7.
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Baden L, Walsh S, Seaman M, Cohen Y, Johnson J, Licona J, et al.
J Infect Dis . 2018 Apr; 218(4):633-644. PMID: 29669026
Background: Mosaic immunogens are bioinformatically engineered human immunodeficiency virus type 1 (HIV-1) sequences designed to elicit clade-independent coverage against globally circulating HIV-1 strains. Methods: This phase 1, double-blinded, randomized, placebo-controlled...
8.
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO
Kakuda T, Brochot A, Green B, Nijs S, Vis P, Opsomer M, et al.
J Clin Pharmacol . 2016 Apr; 56(11):1395-1405. PMID: 27060341
PIANO (NCT00665847) investigated etravirine pharmacokinetics, efficacy, and safety in children and adolescents. Treatment-experienced, HIV-1-infected patients (≥6 to <18 years) received etravirine 5.2 mg/kg twice daily (maximum 200 mg twice daily)...
9.
Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study
Tambuyzer L, Thys K, Hoogstoel A, Nijs S, Tomaka F, Opsomer M, et al.
Antivir Ther . 2015 Nov; 21(4):317-27. PMID: 26566161
Background: We assessed etravirine resistance in treatment-experienced, HIV-1-infected children (n=41)/adolescents (n=60) who received twice-daily etravirine 5.2 mg/kg and a background regimen (boosted protease inhibitor plus nucleoside/nucleotide reverse transcriptase inhibitors, optional...
10.
Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial
Kakuda T, Leopold L, Nijs S, Vandevoorde A, Crauwels H, Bertelsen K, et al.
J Clin Pharmacol . 2015 May; 54(5):563-73. PMID: 25975423
Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) may require treatment with an HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), for example, rilpivirine or etravirine, and an HCV...